- $23.34bn
- $27.11bn
- $3.72bn
Brief: Genmab Revises 2026 Adjusted Operating Profit Guidance To $1.07 Billion To$1.39 Billion
Brief: Genmab Reports H1 Operating Profit Of $555 Million
Brief: Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)
Brief: Genmab Q2 Net Sales Of Darzalex At $4,207 Mln
Europe Research Roundup: Bunzl, Colruyt, Kion Group
Brief: Genmab Announces Tepkinly® In Combination With Lenalidomide And Rituximab Is Approved By The European Commission
Genmab gains after positive EPKINLY combo data
Brief: Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide
Brief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss
Europe Research Roundup: ACS, Endeavour Mining, IHG
Denmark's Genmab Q1 operating profit misses estimates
Brief: Genmab Reports Q1 Operating Profit Of $180 Million
Europe Research Roundup: Barclays, Societe Generale, UBS Group
GS ups Genmab to 'buy' on attractive entry point ahead of catalysts
Europe Research Roundup: Barclays, Societe Generale, UBS Group